Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OHB-607 versus standard neonatal care for prevention of bronchopulmonary dysplasia in extremely premature infants
NL-OMON52648Phase 2Not yet recruiting
- Sponsor
- OHB Neonatology Ltd
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mecasermin rinfabate in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by OHB Neonatology Ltd. Primary endpoint: Incidence of severe bronchopulmonary dysplasia or death by 36 weeks postmenstrual age. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
mecasermin rinfabate
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NL-OMON52648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52648.